Page 108 - 南京医科大学自然版

第44卷第12期
·1722 · 南 京 医 科 大 学 学 报 2024年12月

diovasc Drugs Ther，2023，DOI：10.1007/s10557 ⁃ 023 ⁃ （8）：1177-1182
07530⁃4 ［27］NAGAO T，INDEN Y，YANAGISAWA S，et al. Differences
［24］TANG S，HU X，BAO W，et al. Development and valida⁃ in activated clotting time among uninterrupted anticoagu⁃
tion of a nomogram model affecting the ACT targeting rate lants during the periprocedural period of atrial fibrillation
during radiofrequency ablation of atrial fibrillation in Chi⁃ ablation［J］. Heart Rhythm，2015，12（9）：1972-1978
na［J/OL］. Cardiovasc Drugs Ther，2023，DOI：10.1007/ ［28］KISHIMA H，MINE T，FUKUHARA E，et al. A novel pro⁃
s10557⁃023⁃07450⁃3 tocol for initial heparin administration during catheter ab⁃
［25］WINKLE R A，MEAD R H，ENGEL G，et al. Atrial fibril⁃ lation for atrial fibrillation in patients taking direct oral
lation ablation using open⁃irrigated tip radiofrequency：ex⁃ anticoagulants［J］. Heart Vessels，2019，34（5）：832-841
perience with intraprocedural activated clotting times ≤ ［29］VIENNE M，HAAS E，WIPF T，et al. Adjusted calcula⁃
210 seconds［J］. Heart Rhythm，2014，11（6）：963-968 tion model of heparin management during cardiopulmo⁃
［26］ZELJKOVIC I，BRUSICH S，SCHERR D，et al. Differences nary bypass in obese patients：a randomised controlled
in activated clotting time and total unfractionated heparin trial［J］. Eur J Anaesthesiol，2018，35（8）：613-620
dose during pulmonary vein isolation in patients on differ⁃ ［收稿日期］ 2024-09-19
ent anticoagulation therapy［J］. Clin Cardiol，2021，44 （本文编辑：唐 震）

（上接第1714页） ［22］OOSTERHOF T H，DARWEESH S K L，BLOEM B R，et
志，2018，35（2）：206-213 al. Considerations on how to prevent Parkinson’s disease
［17］ESPAY A J ，BONATO P，NAHAB F B et al. Movement through exercise［J］. J Parkinsons Dis，2024，14（s2）：
disorders society task force on technology. Technology in S395-S406
Parkinson’s disease：challenges and opportunities［J］. ［23］CAMICIOLI R，MORRIS M E，PIERUCCINI⁃FARIA F，
Mov disord，2016，31（9）：1272-1282 et al. Prevention of falls in Parkinson’s disease：guide⁃
［18］ESPAY A J，HAUSDORFF J M，SÁNCHEZ⁃FERRO Á， lines and gaps［J］. Mov Disord Clin Pract，2023，10（10）：
et al. A roadmap for implementation of patient⁃centered 1459-1469
digital outcome measures in Parkinson’s disease ob⁃ ［24］RAJAN S，KAAS B. Parkinson’s disease：risk factor mod⁃
tained using mobile health technologies［J］. Mov Disord， ification and prevention［J］. Semin Neurol，2022，42（5）：
2019，34（5）：657-663 626-638
［19］MESTRE T A，FERESHTEHNEJAD S M，BERG D，et al. ［25］MARTÍNEZ⁃FERNÁNDEZ R，MÁÑEZ⁃MIRÓ J U，RO⁃
Parkinson’s disease subtypes：critical appraisal and rec⁃ DRÍGUEZ⁃ROJAS R，et al. Randomized trial of focused
ommendations［J］. J Parkinsons Dis，2021，11（2）：395-404 ultrasound subthalamotomy for Parkinson’s disease［J］.
［20］BLOEM B R，MARKS W J JR，SILVA DE LIMA A L，et N Engl J Med，2020，383（26）：2501-2513
al. The personalized Parkinson project：examining disease ［26］BRABENEC L，MEKYSKA J，GALAZ Z，et al. Speech
progression through broad biomarkers in early Parkinson’s disorders in Parkinson’s disease：early diagnostics and ef⁃
disease［J］. BMC Neurol，2019，19（1）：160 fects of medication and brain stimulation［J］. J Neural
［21］RAMIG L，HALPERN A，SPIELMAN J，et al. Speech Transm，2017，124（3）：303-334
treatment in Parkinson’s disease：randomized controlled ［收稿日期］ 2024-05-14
trial（RCT）［J］. Mov Disord，2018，33（11）：1777-1791 （本文编辑：戴王娟）